^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zansecimab (LY3127804)

    i
    Other names: LY 3127804, LY3127804
    Associations

    News

    Trials
    Company:
    Eli Lilly
    Drug class:
    Angiopoietin 2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=62, Terminated, Eli Lilly and Company | N=105 --> 62 | Completed --> Terminated
    Enrollment change • Trial termination
    |
    paclitaxel • Cyramza (ramucirumab) • zansecimab (LY3127804)
    over5years
    First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. (PubMed, Br J Cancer)
    LY3127804 monotherapy and its combination with ramucirumab are well tolerated. LY3127804 20 mg/kg was the recommended Phase 2 dose.
    Clinical • P1 data • Journal • Combination therapy
    |
    ANGPT2 (Angiopoietin 2)
    |
    zansecimab (LY3127804)